Five years of experience with hydroxyurea in children and young adults with sickle cell disease

Blood

Volumn 97, Issue 11, 2001, Pages 3628-3632

  Ferster, Alina ^{a,b,c,d,e,f,g}   Tahriri, Parvins ^{a,b,c,d,e,f,g}   Vermylen, Christiane ^{a,b,c,d,e,f,g}   Sturbois, Geneviève ^{a,b,c,d,e,f,g}   Corazza, Francis ^{a,b,c,d,e,f,g}   Fondu, Pierre ^{a,b,c,d,e,f,g}   Devalck, Christine ^{a,b,c,d,e,f,g}   Dresse, Marie F ^{a,b,c,d,e,f,g}   Feremans, Walter ^{a,b,c,d,e,f,g}   Hunninck, Kathleen ^{a,b,c,d,e,f,g}   Toppet, Michele ^{a,b,c,d,e,f,g}   Philippet, Pierre ^{a,b,c,d,e,f,g}   Van Geet, Chris ^{a,b,c,d,e,f,g}   Sariban, Eric ^{a,b,c,d,e,f,g}  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d Clinique de l'Espérance   (Belgium)

^e Centre Hospitalier Regional de La Citadelle   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA;

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; STROKE; TRANSFUSION; TRANSIENT ISCHEMIC ATTACK;

EID: 0035383785     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3628     Document Type: Article

References (22)

1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. N Engl J Med. 1991;325:11-16.
2. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 1990;27:360-376.
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330: 1639-1644.
4. Powars D, Weideman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine. 1988;67:66-76.
5. Powars D. Sickle cell anemia: beta-S-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol. 1991;28:202-208.
6. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
7. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive "switching" agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine. 1996;75:300-326.
8. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88:1960-1964.
9. Ohene-Frempong K, Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next? Semin Hematol. 1997;34:30-41.
10. Vermylen C, Fernandez-Robles E, Ninane J, Cornu G. Bone marrow transplantation in 5 children with sickle cell anemia. Lancet. 1988;1: 1427-1428.
11. Ferster A, Devalck C, Azzi N, Fondu P, Toppet M, Sariban E. Bone marrow transplantation for severe sickle cell anemia. Br J Haematol. 1992;80: 102-105.
12. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: the European experience. Am J Pediatr Hematol Oncol. 1994;16:1821.
13. Vemylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22:1-6.
14. De Montalembert M, Belloy M, Bernaudin F, et al. Three year follow-up of hydroxyurea treatment in children with sickle cell disease. The French Study Group on Sickle Cell Disease. Am J Pediatr Heamatol Oncol. 1997;19:313-318.
15. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood. 1999;94:1550-1554.
16. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al., and the Cooperative Study of Sickle Cell Disease. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91: 288-294.
17. Pegelow C, Adams RJ, McKie V, Abboud M, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899.
18. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94:3022-3026.
19. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84:643-649.
20. Best PJ, Daoud MS, Pittelkow MR, Petit RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med. 1998;128:29-32.
21. Nguyen TV, Margolis DJ, Hydroxyurea and lower leg ulcers. Cutis. 1993;52:217-219.
22. Davies SC, Beuzard Y, Borgna-Pignatti C, et al. The effect of hydroxyurea in sickle cell disease: a European registry of benefits and toxicity [abstract]. Haematology. 1999;84:PO-0980.